IQVIA Holdings Inc. $IQV Stock Holdings Increased by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 5.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,656 shares of the medical research company’s stock after purchasing an additional 1,600 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in IQVIA were worth $4,989,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of IQV. Canada Pension Plan Investment Board increased its position in IQVIA by 7.3% in the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock worth $810,069,000 after purchasing an additional 312,807 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after buying an additional 798,534 shares in the last quarter. Nordea Investment Management AB increased its holdings in IQVIA by 41.7% in the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after buying an additional 606,391 shares during the last quarter. American Century Companies Inc. increased its holdings in IQVIA by 26.8% in the first quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock worth $253,695,000 after buying an additional 304,258 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in IQVIA by 2.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock worth $251,852,000 after buying an additional 40,699 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research reports. Citigroup increased their price objective on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a report on Wednesday. Barclays increased their price objective on IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a report on Thursday, October 2nd. Stifel Nicolaus increased their price objective on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a report on Wednesday. HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the stock from $195.00 to $235.00 in a report on Thursday, October 9th. Finally, JPMorgan Chase & Co. increased their price objective on IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $244.48.

IQVIA Trading Down 0.7%

Shares of IQV stock opened at $216.30 on Friday. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $225.91. The company has a quick ratio of 0.84, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The business’s 50 day moving average is $196.62 and its two-hundred day moving average is $173.32. The company has a market cap of $36.77 billion, a PE ratio of 29.67, a price-to-earnings-growth ratio of 2.39 and a beta of 1.32.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.